



Sonus Pharmaceuticals To Hold Second Quarter Conference Call On July 11, 2001

BOTHELL, Washington, July 5, 2001-Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) announced today that it will release financial results for the second quarter and hold its quarterly conference call on July 11, 2001.

The conference call will be held at 1:30 P.M. PDT, 4:30 P.M. EDT. To access the conference call via live webcast, visit Sonus' web site at www.sonuspharma.com/investor.html (under calendar of events). The webcast will be archived on the Company's web site for approximately 30 days following the broadcast.

Sonus Pharmaceuticals, Inc., located near Seattle, Washington, is engaged in the research and development of therapeutic drug delivery products based on its proprietary emulsion formulation technology. The Company's lead product is S-8184, a new formulation of paclitaxel for cancer therapy, currently in a Phase 1 clinical study. In preclinical development, Sonus is also developing S-2646, a reformulation of a cardiac drug for the treatment of rapid, life-threatening heart rhythms; and S-9156, a synthetic blood substitute product.

The Company's news releases and other corporate information are available on its web site at www.sonuspharma.com.

Contact: Pamela Dull, Sonus Pharmaceuticals, Inc. (425) 487-9500, Ext. 255.

Certain of the statements made in this press release are forward-looking such as those, among others, relating to the development of drug delivery and oxygen delivery products and potential applications for these products. As discussed in the Sonus annual report on Form 10-K filed with the Securities and Exchange Commission on March 7, 2001, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: The Company's products will require extensive clinical testing and approval by regulatory authorities. Such approvals are lengthy and expensive and may never occur, and may be subject to certain other regulatory requirements; there can be no assurance that Sonus will be successful in its efforts to develop drug delivery and oxygen delivery products; there can be no assurance that Phase 1 studies for S-8184 will be successful or that increased efficacy will result from the Company's emulsion-based formulation; there can be no assurance that Sonus will complete preclinical trials with S-2646 and S-9156; the Company's results from operations have varied and will continue to vary from quarter to quarter and will depend upon, among other factors, timing and cost of clinical trials planned by Sonus and receipt of collaborative partner payments, if any; there can be no assurance that the Company will receive any future collaborative partner payments or that its cash requirements will be met by any such payments; and Sonus intends to seek external financing through available means, which may include debt and/or equity financing or the licensing or sale of proprietary or marketing rights, and there can be no assurance that financing will be available on acceptable terms, if at all.